Acitretin Side Effects
Acitretin causes side effects in most patients, with mucocutaneous effects (lip dryness, skin peeling, hair loss) being nearly universal, while serious concerns include severe teratogenicity requiring 3 years of contraception after stopping, hyperlipidemia in 20-40% of patients, and rare but potentially fatal complications like pancreatitis and pseudotumor cerebri. 1, 2
Most Common Side Effects (Occur in Majority of Patients)
Mucocutaneous Effects
- Lip dryness (cheilitis): Occurs in nearly all patients and is the most frequent side effect 1
- Skin changes: Thinning, redness, scaling, and peeling—particularly on palms and soles—can make walking and grasping objects difficult for many patients 1
- Hair loss: Occurs in up to 75% of patients, though frank alopecia affects <10% 1
- Dry eyes and mucous membranes: Leads to nosebleeds, rhinitis, photophobia, xerophthalmia, conjunctivitis, and contact lens intolerance 1
- Nail changes: Nail fragility, paronychia, and periungual pyogenic granuloma 1
- Dry mouth, thirst, stomatitis, gingivitis, taste disturbances 1
These mucocutaneous effects are dose-dependent and usually resolve with dose reduction or drug discontinuation 1.
Serious Metabolic Side Effects
Hyperlipidemia (Critical for Cardiovascular Risk)
- Triglyceride elevation: Occurs in 20-40% of patients, proportional to dose 1
- Cholesterol elevation: Seen in 10-30% of patients 1
- HDL decrease: Occurs in approximately 40% of patients 1
- Clinical significance: The altered LDL/HDL ratio increases cardiovascular risk, and triglycerides >800 mg/dL are associated with fatal fulminant pancreatitis 2
Monitoring requirement: Check fasting lipids before treatment and every 1-2 weeks until stable (usually 4-8 weeks), then regularly throughout treatment 2. Patients with diabetes, obesity, alcoholism, or family history require more frequent monitoring 1.
Hypoglycemia Risk
Increased risk when combined with antidiabetic agents; monitor glucose more frequently in diabetic patients during early treatment 1.
Life-Threatening Side Effects (Rare but Critical)
Teratogenicity (Most Critical Concern)
- Absolute contraindication in pregnancy and breastfeeding 1, 2
- Fetal abnormalities include: Meningomyelocele, meningoencephalocele, multiple synostoses, facial dysmorphia, syndactyly, absent terminal phalanges, hip/ankle/forearm malformations, cardiovascular malformations, skull and cervical vertebrae alterations 1, 2
- Contraception requirement: Must use 2 effective forms simultaneously for 4 weeks before, during, and 3 years after stopping treatment 1, 2
- Alcohol prohibition: Women of childbearing potential must avoid alcohol during treatment and for 2 months after, as alcohol converts acitretin to etretinate (much longer half-life, extending teratogenic risk) 1, 2
Pancreatitis
Can occur with or without hypertriglyceridemia; fatal fulminant pancreatitis reported with triglycerides >800 mg/dL 2.
Pseudotumor Cerebri (Benign Intracranial Hypertension)
- Presentation: Papilledema, headache, nausea, vomiting, visual disturbances 2
- Action required: Immediate discontinuation and neurological referral if papilledema present 2
- Contraindication: Never combine with tetracyclines or minocycline (increases intracranial pressure risk) 1, 2
Capillary Leak Syndrome
Features include localized/generalized edema, weight gain, fever, hypotension, rhabdomyolysis, myalgias, neutrophilia, hypoalbuminemia, elevated hematocrit. Discontinue immediately if this develops 2.
Exfoliative Dermatitis/Erythroderma
Discontinue immediately if this occurs 2.
Skeletal Abnormalities
In Adults
- Long-term use concerns: Ossification abnormalities, degenerative spurs, anterior bridging of spinal vertebrae, diffuse idiopathic skeletal hyperostosis, ligament calcification 2
- Monitoring: Periodic radiography only warranted with symptoms or long-term use 2
- Clinical trial data: 15% of 380 subjects showed progression of preexisting spinal abnormalities 2
In Children (Special Concern)
- Not recommended in children due to reports of premature epiphyseal closure, skeletal hyperostosis, extraosseous calcification, and decreased bone mineral density 1, 2
- If used: Carefully monitor growth parameters and bone development with growth charts 1
Ophthalmologic Effects
Dry eyes (23%), eye irritation (9%), brow/lash loss (5%), and less commonly: blepharitis, blurred vision, conjunctivitis, corneal abnormalities, cataracts, decreased night vision, diplopia 2. Discontinue and obtain ophthalmologic evaluation if visual difficulties occur 2.
Hepatotoxicity
- Liver enzyme elevations can occur 1
- Contraindicated with hepatic impairment (enzymes >2× normal), hepatitis, alcohol abuse 1
- Drug interaction: Increased liver toxicity risk with methotrexate—avoid concomitant use 1
Other Notable Effects
- Initial psoriasis worsening: Can occur in first 4 weeks of treatment 1
- "Retinoid dermatitis": May resemble unstable psoriasis in up to 25% of patients on high-dose therapy 1
- Photosensitivity: UV radiation effects enhanced; avoid excessive sun exposure and sun lamps 1
- Skin fragility: Avoid waxing for hair removal 1
Critical Drug Interactions
- Tetracyclines/minocycline: Contraindicated (pseudotumor cerebri risk) 1, 2
- Methotrexate: Avoid (hepatotoxicity risk) 1
- Mini-pill (progestin-only): Decreased efficacy; use combined oral contraceptives instead 1
- Phenytoin: Reduced protein binding (clinical significance unknown) 1
- Corticosteroids: Increased hyperlipidemia risk 1
- Vitamin A supplements: Do not exceed 2400-3000 IU daily 1